Product Details

Pediatric Trials On the Verge

As FDAMA Section 111 approaches, investigative sites and CROs are rapidly building capabilities to exploit the expected growth in pediatric clinical trials.

At this time, major medical centers appear to be the best positioned investigative site segment to grab the pediatric clinical trials market.

At Last! Development Cycle Times Shorten

Reversing a 12-year trend, clinical phase (I-III) durations from 1996 to 1998 are 18% faster. In that same period, regulatory approval times have declined by 30%.

Sponsors will need to continuously improve collaborative effectiveness with CROs and investigative sites to maintain and exceed clinical cycle time acceleration

Also in this issue:

• CentreStage Europe: European CRO Market Outpaces US Market
• Eye On Urinary Incontinence